SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Avadel AVDL
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tom pope who wrote (202)9/25/2007 12:13:40 AM
From: Robohogs   of 240
 
From Rodman:

GlaxoSmithKline’s Coreg CR increased 8% and 10% in new and total prescription volume, respectively, despite the
introduction of generic Coreg. Total Coreg CR prescriptions are now at their highest levels to date, with 42,873
prescriptions recorded. Coreg CR’s share of prescriptions written for the Coreg franchise increased to 30% and
22% of new and total prescriptions, from 20% and 14% the previous week. This is due to the launch of generic
immediate release Coreg. Coreg prescriptions declined 37% and 38% in new and total prescriptions, respectively.

My add: The 42,873 is up 5% week over week but only up 1% vs. "normal" week 2 weeks ago. New Rx's lagging and are off from recent highs just over 20K.

Jon
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News